Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
KW-2450
i
Other names:
KW-2450
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Kyowa Kirin
Drug class:
IGF-1R inhibitor
Related drugs:
‹
BMS-754807 (10)
AMG 479 (10)
ASP7487 (7)
AZD3463 (2)
GSK 1838705A (2)
SY-707 (1)
CP-751,871 (1)
BMS-536924 (0)
FPI-1434 (0)
IGV-001 (0)
LX-101 (0)
NVP-ADW742 (0)
NVP-AEW541 (0)
NVP-TAE226 (0)
teprotumumab-trbw (0)
XL228 (0)
IMC A12 (0)
MK 0646 (0)
MEDI-573 (0)
MM-141 (0)
AXL1717 (0)
SCH 717454 (0)
BMS-754807 (10)
AMG 479 (10)
ASP7487 (7)
AZD3463 (2)
GSK 1838705A (2)
SY-707 (1)
CP-751,871 (1)
BMS-536924 (0)
FPI-1434 (0)
IGV-001 (0)
LX-101 (0)
NVP-ADW742 (0)
NVP-AEW541 (0)
NVP-TAE226 (0)
teprotumumab-trbw (0)
XL228 (0)
IMC A12 (0)
MK 0646 (0)
MEDI-573 (0)
MM-141 (0)
AXL1717 (0)
SCH 717454 (0)
›
Associations
News
Trials
Filter by
Latest
7ms
Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=13, Completed, Kyowa Kirin Co., Ltd. | N=72 --> 13
7 months ago
Enrollment change • Metastases
|
KW-2450
7ms
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=11, Terminated, Kyowa Kirin Co., Ltd. | Phase classification: P1/2 --> P1
7 months ago
Phase classification • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 overexpression
|
lapatinib • letrozole • KW-2450
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login